Butterfly Network Inc. stocks have been trading up by 9.2 percent after upbeat coverage of its AI-powered handheld ultrasound platform.
Click Here for a Millionaire's POV on Trading BFLY
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For BFLY Traders
- Midjourney Medical’s full-body tomographic scanner embeds Butterfly Ultrasound-on-Chip modules under a licensing deal that may deliver up to $74M over five years with room to scale.
- Each Midjourney scanner currently uses 40 Butterfly modules, with future generations expected to need more, deepening the BFLY commercial opportunity if volumes ramp.
- Regulatory clearance in Brazil lets Butterfly Network start selling its iQ+ and iQ3 handheld ultrasound devices via distributors into Latin America’s largest medical device market.
- Partner Aleph Neuro generated high-resolution, non-invasive 3D brain images using Butterfly’s platform, expanding the potential of Butterfly Embedded beyond point-of-care ultrasound.
- BFLY shares have swung hard, dropping 18.8% to $7.22 on 2026/06/22, then later spiking 17.3% to $9.01 in another session.
Live Update At 14:02:43 EDT: On Thursday, July 09, 2026 Butterfly Network Inc. stock [NYSE: BFLY] is trending up by 9.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Butterfly Network, traded as BFLY, is acting like a classic high-growth, high-volatility story. Revenue over the last year sits around $97.61M, growing at a double‑digit clip, but the company is still deep in the red. BFLY’s latest quarter showed $26.53M in revenue with a solid 49.2% gross margin, yet operating losses remain heavy, with an EBIT margin around -72%.
That loss profile shows up in the cash flow. BFLY burned about $13.89M in operating cash in the recent quarter and posted roughly -$14.84M in free cash flow. The balance sheet, however, gives the company time. Butterfly Network holds about $137.95M in cash and short-term investments, carries modest long-term debt near $17.02M, and sports a current ratio of roughly 4, signaling plenty of near-term liquidity.
More Breaking News
- BFLY Stock Jumps As Brazil Launch And Licensing Deals Fuel Momentum
- FLNC Stock Slides As AI Battery Demand Story Heats Up
- VRAX Stock Explodes As Traders Chase Wild Momentum
- American Airlines Stock Wobbles As Analyst Downgrade Meets Fuel Shock
On valuation, BFLY trades at about 12.18 times sales and 6.55 times book value, rich for a medtech name with negative earnings. But that is exactly the set-up traders like: strong growth, disruptive tech, and a market willing to pay up, as long as the story keeps delivering catalysts.
Why Traders Are Watching BFLY Now
BFLY is back on a lot of watchlists because its story just picked up several powerful catalysts at once. First, the Midjourney Medical deal. Their newly launched full‑body tomographic ultrasound scanner uses Butterfly Network’s Ultrasound‑on‑Chip modules under a co‑development and licensing arrangement. Management has said this pipeline could be worth up to $74M over five years, and that is before any upside from broader market adoption.
Butterfly Network later confirmed a key detail: each Midjourney scanner currently packs 40 Butterfly Ultrasound‑on‑Chip modules. If Midjourney Medical sells more systems or future generations step up module counts, BFLY’s revenue per unit grows with almost no added sales cost. That kind of embedded, scalable content is exactly what momentum traders seek in hardware‑plus‑licensing names.
At the same time, Butterfly Network is expanding its footprint with a concrete geographic move. BFLY secured regulatory clearance in Brazil and kicked off commercial sales of its iQ+ and iQ3 handheld devices through distributors. Brazil is Latin America’s largest medical device market and a fast‑growing ultrasound region, spanning busy urban hospitals and underserved rural clinics. That creates both volume potential and a strong “democratizing imaging” narrative that BFLY already leans on.
Then there’s the Aleph Neuro news. Using Butterfly’s platform, Aleph generated very high‑resolution, non‑invasive 3D brain images, showcasing Butterfly Embedded as more than just bedside imaging. Traders looking beyond the next quarter see optionality here: neuro, advanced imaging, and more licensing paths layered on top of BFLY’s handheld core.
All of this comes against a wild tape. BFLY plunged 18.8% to $7.22 on 2026/06/22, then ripped 17.3% in a later session to $9.01. Add a Form 4 insider ownership change and an appearance in TD Cowen’s Emerging Growth Call Series on 2026/06/18, and you have a name where sentiment and news flow can flip the chart quickly.
Conclusion
For short‑term traders, BFLY’s recent price action and intraday tape tell the story. The daily chart shows a surge from the mid‑$5s to above $8 in a few weeks, with sharp swings like the drop to $7.27 on 2026/06/22 and rebounds toward $8–$9 afterward. The 5‑minute data reinforces that BFLY now trades in a tight intraday range around $8, consolidating after big moves — classic digestion after a momentum run.
Behind that volatility, Butterfly Network’s fundamentals are still those of a scaling medtech platform, not a mature cash cow. Losses remain large, but BFLY is steadily building high‑margin licensing channels through Midjourney Medical and Aleph Neuro, while pushing its iQ+ and iQ3 devices into Brazil and beyond. Traders who track narrative plus numbers will see a pattern: cash runway in place, strong gross margins, and multiple shots on goal via embedded Ultrasound‑on‑Chip deals.
None of this is a prediction or a recommendation. It is an educational breakdown of how BFLY is evolving as a trading vehicle. As Tim Sykes loves to say, “Volatility is opportunity, but only if you respect risk and cut losses quickly.” As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. With BFLY, the opportunity side is clear — the risk side is just as real, and serious traders will treat both with equal focus.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.